Italia markets closed
Dow Jones
38.849,75 +50,76 (+0,13%) Nasdaq
17.159,73 +26,60 (+0,16%) Nikkei 225
39.038,16 +354,23 (+0,92%) EUR/USD
1,0761 -0,0043 (-0,40%) Bitcoin EUR
64.866,81 +22,59 (+0,03%) CMC Crypto 200
1.450,60 +3,93 (+0,27%)
SWTX Sep 2024 40.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 12:01PM EDT. Mercato aperto.
| Chiusura precedente | 5,45 |
| Aperto | 5,45 |
| Denaro | 3,40 |
| Domanda | 7,10 |
| Prezzo d'esercizio | 40,00 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 5,45 - 5,45 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 17 |
GlobeNewswireSpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
– Presented additional Phase 3 DeFi data at ASCO demonstrating clinically significant reductions in pain and substantial reductions in tumor volume and T2 hyperintensity with nirogacestat treatment – – Completed enrollment of Phase 2 trial evaluating nirogacestat in patients with ovarian granulosa cell tumors – – Highlighted encouraging Phase 1 and 2 clinical data from emerging pipeline programs at AACR and EHA – STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (
© 2024 Yahoo. Tutti i diritti riservati.